Kingsbury Capital Investment Advisors LLC Buys 762,367 Shares of Alzamend Neuro, Inc. $ALZN

Kingsbury Capital Investment Advisors LLC grew its position in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 134.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,329,100 shares of the company’s stock after acquiring an additional 762,367 shares during the quarter. Alzamend Neuro comprises about 1.3% of Kingsbury Capital Investment Advisors LLC’s portfolio, making the stock its 18th largest position. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC raised its holdings in shares of Alzamend Neuro by 33.7% in the fourth quarter. Geode Capital Management LLC now owns 27,506 shares of the company’s stock worth $50,000 after buying an additional 6,928 shares during the period. Institutional investors and hedge funds own 49.61% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 31st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

Alzamend Neuro Price Performance

ALZN opened at $1.66 on Monday. The firm has a market capitalization of $8.02 million, a PE ratio of -0.57 and a beta of 0.23. The business’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.37. Alzamend Neuro, Inc. has a 1 year low of $0.84 and a 1 year high of $2.68.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Wednesday, July 22nd. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.07). As a group, sell-side analysts expect that Alzamend Neuro, Inc. will post -1.05 EPS for the current year.

Alzamend Neuro Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.